Skip to NavigationSkip to content

Johnson & Johnson

Five most talked about mergers and acquisitions of 2016

Published on 27/01/17 at 12:55pm

2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of Actelion, swiftly followed by Celgene announcing that it was poised to acquire Delinia in a $775 million deal. As a result, we thought we’d take a look at some of the largest deals of last year that changed the face of the pharmaceutical industry.

J&J finally seals $30 billion deal for Actelion

Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working out at a deal of $280 a share. The deal excludes the R&D unit of Actelion, which will be spun out into a new publicly traded company, named R&D NewCO, under the leadership of Actelion founder and CEO Jean-Paul Clozel.

J&J to reveal drug price increases next month

Next month, Johnson & Johnson will reveal the average price increases of its prescription drugs in a move to increase its transparency with patients; the information due to be released by the company will include the list price and net price.

Actelion acquisition hokey-cokey continues with J&J returning to table

The Actelion takeover saga continues with Johnson & Johnson back in the game, and now re-entering into exclusive negotiations. Actelion had previously been engaged in discussion with Johnson & Johnson before negotiations broke off, with Sanofi entering into the arena.

J&J's largest India site to finally operate by 2018

Johnson & Johnson has reportedly announced that its manufacturing plant in Telangana, India, its largest site in the country, is due to be completed and fully operational by 2018, according to a top official knowledgeable on the matter.

Sanofi eyes Actelion merger as J&J backs down

After days of negotiations, Johnson and Johnson has stepped down from its attempts to acquire Swiss blood-pressure specialist Actelion, while Sanofi steps up to the plate with a reportedly larger valuation of the company.

J&J and Genmab’s drug races to second line treatment approval

Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been approved as a combination therapy for second-line treatment of bone marrow cancer. Janssen entered into a worldwide agreement to license and develop Darzalex back in 2012.

The drug Darzalex was trialled alongside Celgene’s Revlimid and Takeda’s Velcade, with the results being enough to convince the FDA to approve the combination therapy three months ahead of schedule.

GSK/J&J release how their drug measures up against Humira

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options for adults suffering from active rheumatoid arthritis, in comparison with market leader Humira. The trial evaluated the drug sirukumab, co-developed by the two companies, which is a human anti-interleukin (IL)-6 monoclonal antibody.

Janssen's Crohn's treatment licensed for UK use

Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European Commission for use in the UK as an option for moderate to severely active Crohn’s disease in adult patients who do not respond adequately to conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.

Collaboration on new therapeutic vaccine for HIV shows promise

Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into a new approach to combatting human immunodeficiency virus (HIV-1). The study was a collaboration between researchers at the Beth Israel Deaconess Medical Center (BIDMC), alongside scientists at Walter Reed Army Institute of Research (WRAIR), Janssen and Gilead Sciences.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches